Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 2

Нюансы и алгоритмы антикоагулянтной терапии венозных тромбоэмболических осложнений на всех этапах лечения. Позиции апиксабана
Р.М. Линчак

References

1. Dentali F, Ageno W, Pomero F, Fenoglio L, Squizzato A, Bonzini M. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thrombosis and Haemostasis 2016 Jan;115(2):399-405.
2. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circulation Research 2016 Apr;118(9):1340-7.
3. Chalikaias GK, Tziakas DN, Stakos DA, Konstantinides SV. Management of acute pulmonary embolism: a contemporary, risk-tailored approach. Hellenic Journal of Cardiology 2010 Sep-Oct;51(10):437-50.
4. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Áinle FN, Prandoni P, Pruszczyk P, Righini M, Van Belle TE, Zamorano JL; ESC Scientific Document Group. 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal 2019 Jan;00:1-61.
5. Kiriyenko AI, Andriyashkin VV, Leontyev SG, Mironov AV. Pulmonary embolism. Cardiology: national guidelines. Shlyakhto EV. 2nd ed., revised. Moscow: Geotar-Media; 2015: 712-22 (In Russian).
6. Averkov OV, Vechorko VI, Shapsigova OA. Apixaban application at different stages of management of patients with pulmonary embolism. Medical Council 2018;21:8-15 (In Russian).
7. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schelong S, Eriksson H, Baanstra D, Schee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The New England Journal of Medicine 2009 Dec;361(24):2342-52.
8. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014 Feb;129(7):764-72.
9. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine 2013 Aug;369(8):799-808.
10. The EINSTEIN-DTV Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine 2010 Dec;363(26):2499-510.
11. The EINSTEIN-PE Investigators; Büller HR, Prins MH, Lensin AWA, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England Journal of Medicine 2012 Apr;366(14):1287-97.
12. Yavelov IS. Main indications for use of oral anticoagulants: how to choose the optimal drug. Good Clinical Practice 2017;3:53-60 (In Russian).
13. Van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis 2014;12(3):320-8.
14. Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and Expert Panel Report. Chest 2016 Feb;149(2):315-52.
15. Raskob G, Gallus A, Sanders P, Thompson JR, Agnelli G, Buller HR, Cohen AT, Ramacciotti E, Weitz JI. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis 2015 Apr;115(4):35-43.
16. Napalkov DA, Sokolova AA, Fomin VV. Data of clinical practice as a tool for choice of direct oral anticoagulant. Rational Pharmacotherapy in Cardiology 2017;13(1):95-9 (In Russian).
17. Weycker D, Li X, DeVecchis G, Lee T, Hamilton M, Luo X, Vo L, Mardekian J, Pan X, Burns L, Atwood M, Hanau A, Cohen AT. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thrombosis and Haemostasis 2018 Nov;118(11):1951-61.
18. Dawwas G, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population based cohort analysis. The Lancet. Haematology 2019 Jan;6(1):e20-8.
19. Aryal M, Gosain R, Donato A, Yu H, Katel A, Bhandari A, Dhital YR, Kouides PA. C2381-7. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Advances 2019;3(15):2381-7.
20. Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice. A cohort study. Annals of Internal Medicine 2020 Apr;172(7):463-73.
21. Gupta K, Trocio J, Keshishian A, Zhang Q, Dina Q, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. department of defense population. Journal of Managed Care and Special Pharmacy 2018 Nov;24(11):1116-25.
22. Bonde A, Martinussen T, Lee C, Lip GYH, Staerk L, Bang CN, Bhattacharya J, Gislason G, Torp-Pedersen C, Bjerring Olesen JB, Hlatky MA. Rivaroxaban versus apixaban for stroke prevention in atrial fibrillation an instrumental variable analysis of a nationwide cohort. Circulation. Cardiovascular Quality and Outcomes 2020 Apr;13(4):e006058.
23. Rutherford OC, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S. Comparison of dabigatran, rivaroxaban and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. European Heart Journal. Cardiovascular Pharmacotherapy 2020 Apr;6(2):75-85.
24. Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA; MARVELOUS Collaborators. Long-term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019 Jul;366:l4363.
25. Schulman S, Kearon C, Kakkar A, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Pharm MS, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. The New England Journal of Medicine 2013;368:709-18.
26. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine 2010 Dec;363(26):2499-510.
27. Agnelli G, Buller HR, Am C, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. The New England Journal of Medicine 2013 Feb;368(8):699-708.
28. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf JB, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Verhamme SD, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. The New England Journal of Medicine 2017 Mar;376(13):1211-22.
29. Russian clinical guidelines for the diagnosis, treatment, and prevention of venous thromboembolic complications. Flebologiya 2015;9(4-2):1-52 (In Russian).
30. Rudakova AV. Cost effectiveness of new oral anticoagulants in treatment and secondary prevention of venous thromboembolism. Rational Pharmacotherapy in Cardiology 2015;11(5):496-503 (In Russian).
31. Kachroo S, Boyd D, Bookhart BK, Joyce LaMori J, Schein JR; Rosenberg DJ; Reynolds MW. Quality of life and economic costs associated with postthrombotic syndrome. American Journal of Health-system Pharmacy 2012 Apr;69(7):567-72.
32. Lin J, Trocio J, Gupta K, Mardekian J, Lingohr-Smith M, Menges B, You M, Nadkarni A. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. Journal of Medical Economics 2017 Sep;20(9):952-61.
33. Amin A, Keshishian A, Vo L, Zhang Q, Dina O, Patel C, Odell K, Trocio J. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for nonvalvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. Journal of Medical Economics 2018 Mar;21(3):244-53.
34. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. Clinical Oncology 2009 Oct;27(29):4839-47.
35. Blom JU. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005 Feb;293(6):715-22.
36. Fedotkin YuA. Prevention of venous thromboembolism in cancer patients. Atherothrombosis 2019;1:8-24 (In Russian).
37. Lee A, Levine M, Baker R, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. The New England Journal of Medicine 2003 Jul;349(2):146-53.
38. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. The New England Journal of Medicine 2018 Feb;378(7):615-24.
39. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer and venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology 2018 Jul;36(20):2017-23.
40. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. The New England Journal of Medicine 2020 Apr;382(17):1599-607.
41. Xiang E, Ahuja T, Raco V, Cirrone F, Green D, Papadopoulos J. Anticoagulation prescribing patterns in patients with cancer. Journal of Thrombosis and Thrombolysis 2018 Jan;45(1):89-98.
42. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X. Safety and effectiveness of apixaban, LMWH, and warfarin among venous thromboembolism patients with active cancer: a retrospective analysis using four us claims databases. Blood 2019;34(Supp 1):326.
43. Wysokinski W, Houghton D, Casanegra A, Vlazy DT, Bott-Kitslaar DM, Froehling DA, Hodge DO, Peterson LG, Mcbane RD. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. American Journal of Hematology 2019 Nov;94(11):1185-92.
44. Shah S, Norby F, Datta Y, Lutsey PL, MacLehose RF, Chen LY, Alonso A. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Advances 2018 Feb;2(3):200-9.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]